Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Discovery Labs’ Second Surfaxin Approvable Letter Highlights CMC Concerns

This article was originally published in The Pink Sheet Daily

Executive Summary

The company does not foresee the need for additional clinical trials.

You may also be interested in...



Third Time’s Not A Charm: Discovery’s Surfaxin Receives “Approvable” Letter

Synthetic surfactant for prevention of respiratory distress syndrome in premature infants is deemed “approvable” by FDA.

Third Time’s Not A Charm: Discovery’s Surfaxin Receives “Approvable” Letter

Synthetic surfactant for prevention of respiratory distress syndrome in premature infants is deemed “approvable” by FDA.

Discovery Enters Phase II Trial Of Surfaxin For Acute Respiratory Failure In Children

Firm takes next step in its goal to develop compound for wide range of respiratory problems in children and adults.

Related Content

Topics

UsernamePublicRestriction

Register

LL005491

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel